DIDACTIC acquired by UI INVESTISSEMENT

This transaction is a strategic corporate carve-out and vertical integration wherein Novonesis fully acquires the sales and distribution activities of the Feed Enzyme Alliance from its long-term joint venture partner, dsm-firmenich. Supported by a fully committed debt financing package, this operation effectively dissolves the historical alliance, granting Novonesis absolute control over the entire commercial value chain. The primary strategic rationale underpinning this acquisition is to directly combine the acquirer's established innovation and production capabilities with the target's extensive global go-to-market network. This powerful consolidation will significantly accelerate Novonesis's market penetration, unlock substantial revenue synergies, and solidify its undisputed leadership position within the global animal nutrition and biosolutions industry.

The secondary buyout of 100% of Medical International Research by Quadrivio Group triggers the complete exit of the incumbent private equity sponsor Aksìa SGR. This ownership transition follows an operational phase marked by an annualized revenue expansion and the successful launch of subscription-based software services. The secondary transaction alters the capital structure to support a broader consolidation strategy amid rising global demand for decentralized respiratory diagnostics. The incoming capital is structured to fund geographic expansion into historically underpenetrated, highly solvent Northern European healthcare jurisdictions including Germany and the United Kingdom. Institutional debt backing for the buyout combines a super-senior revolving credit line with a private unitranche facility designed to provide immediate funding for strategic add-on acquisitions.

EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88.92% of the share capital and voting rights (including treasury shares). The offer was initiated to take the company private and provide the management team, led by Denis Fortier, with the flexibility to pursue an aggressive external growth strategy. While the bid secured a significant majority, the final participation fell just short of the 90% threshold required for a mandatory squeeze-out (retrait obligatoire). Consequently, the conditional additional price of €1.25 per share (linked to reaching the 90% mark) will not be paid to tendering shareholders. Despite remaining listed for the time being, the transaction effectively shifts Eurobio into a "private-equity-backed" development phase, allowing for deeper consolidation of the European in vitro diagnostics market.

Naxicap Partners has acquired a majority stake (over 60%) in Global D, marking the company’s first independent LBO following its carve-out from the Menix Group. The remaining capital is held by a dozen managers led by the executive team. The transaction follows a competitive auction process and includes a financing package provided by Capza (unitranche and PIK debt) alongside a capex line from Banque Palatine. This strategic "independence" move follows the parent group's divestment of other assets to industrial giants. The rationale for this new cycle is to support the firm’s internationalization and active buy-and-build strategy, targeting niche acquisitions with revenues between 5 million and 20 million euros to complement its existing technology and geographic reach.

Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products.

Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA. The Anjac family maintains a strong majority. The transaction was coupled with an extension of the existing syndicated credit line to fund future acquisitions.

Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO. The existing executive management team will continue to operate the business independently. The strategic rationale centres on accelerating PetIQ's mission of providing convenient and affordable pet healthcare, investing in marketing and innovation, and pursuing strategic bolt-on acquisitions — initiatives that Bansk believes are better executed outside the constraints of public market ownership.

Agilent Technologies has finalized the acquisition of BIOVECTRA, a move designed to fundamentally expand the group's contract development and manufacturing (CDMO) portfolio into fast-growing therapeutic modalities. The strategic rationale for this transaction centers on a "growth-vector" play, merging the target's world-class manufacturing capabilities in mRNA, pDNA, and LNP formulation with the group’s established leadership in guide RNA and CRISPR technologies. This fusion effectively creates a specialized powerhouse in the gene-editing market, providing the organization with a single-source solution to serve biopharmaceutical partners from early clinical stages to commercial launch. This operation allows the organization to execute a definitive structural expansion of its biopharma offerings by adding sterile fill-finish services and expertise in GLP-1 agonists. By incorporating these high-growth capabilities, the group can now provide a seamless end-to-end workflow that integrates analytical instrumentation with large-scale cGMP manufacturing. The maneuver optimizes the group's positioning in highly attractive industry verticals, sharpening its focus on mission-critical technologies that accelerate therapeutic programs. Ultimately, the partnership solidifies the group’s standing as a primary enabler of clinical innovation, bridging the gap between sophisticated lab-based research and industrialized pharmaceutical production standards.

Nordson Corporation completed its acquisition of Atrion Corporation on August 21, 2024, following the definitive agreement announced on May 28, 2024. The strategic rationale is centered on portfolio expansion within Nordson Medical. Atrion adds proprietary infusion fluid delivery and niche cardiovascular technologies, broadening Nordson’s exposure to adjacent end markets and strengthening its offering in higher-growth medical applications. The combination is highly complementary from both a product and customer standpoint, while also benefiting from Atrion’s FDA-registered manufacturing footprint and patent portfolio. This creates a more comprehensive platform with meaningful cross-sell and integration potential. From a value creation perspective, the transaction supports Nordson’s long-term growth framework by increasing exposure to secular healthcare demand, recurring single-use consumables, and OEM outsourcing trends. Management also highlighted anticipated operational synergies over the first two years of ownership, which should enhance the deal’s attractiveness and support margin expansion over time.

The acquisition of the point-of-care technology platform from the LumiraDx group marks a transformative technical reinforcement of the acquirer's diagnostic ecosystem. The strategic rationale for this transaction centers on a "decentralization" play, merging the target's innovative multi-assay hardware with the group’s vast global commercial and R&D infrastructure. This fusion effectively creates a comprehensive solution set for primary care and remote settings, addressing the global need for timely and affordable diagnostic results outside of centralized facilities. This operation allows for a definitive structural expansion of the group's "patient-centric" vision, covering the entire journey from general practitioner offices to remote healthcare outposts. By incorporating a platform capable of handling diverse modalities (including coagulation and future molecular testing) the organization can now provide a more robust and integrated service for infectious disease management, such as tuberculosis detection in partnership with global health foundations. The maneuver optimizes the group's positioning in low- and middle-income countries where traditional laboratory access is limited. Ultimately, the partnership solidifies the group’s standing as a primary enabler of community-based healthcare innovation, bridging the gap between sophisticated laboratory diagnostics and industrialized point-of-need testing standards.